Prognostic Role of Adjuvant Chemotherapy in Node-Negative (N0), Triple-Negative (TN), Medullary Breast Cancer (MBC) in the Korean Population

PLoS One

Heong Kyu Park¹  Min Hee Hur²  Se Jeong Oh³  Se Ho Park⁴  Young Jin Suh⁵  SeungTaek Lim⁵ 

[1] Breast Cancer Center, Department of Surgery, Gachon University Gill Hospital, 1198, Guwoldong, Incheon, 405-760, Republic of Korea;Department of Surgery, Cheil General Hospital and Women`s Healthcare Center, Dankook University College of Medicine, 17 Seoae-ro 1-gil, Jung-gu, Seoul, 100-380, Republic of Korea;Department of Surgery, Incheon St. Mary`s Hospital, College of Medicine, The Catholic University of Korea, 56 Dongsu-ro, Bupyung-gu, Incheon, 403-720, Republic of Korea;Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea;Division of Breast & Thyroid Surgical Oncology, Department of Surgery, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Jungbu-daero 93, Paldal-gu, Suwon-si, Gyeonggi-do, 442-723, Republic of Korea

关键词: Adjuvant chemotherapy;    Breast cancer;    Cancer chemotherapy;    Histology;    Vascular surgery;    Cancer detection and diagnosis;    Cancer treatment;    Surgical and invasive medical procedures;   

DOI  :  10.1371/journal.pone.0140208

学科分类：医学（综合）

来源: Public Library of Science

【 摘 要 】

Background Despite the favorable prognosis for medullary breast cancer (MBC), the guidelines for the use of adjuvant chemotherapy for MBC have not been clearly established. This study investigated the prognostic role of adjuvant chemotherapy in Korean patients with node-negative (N0), triple-negative (TN) MBC patients. Methods We included data from 252 patients with N0 TN MBC, obtained from the Korean Breast Cancer Registry database. Patients were categorized as those who did not undergo adjuvant chemotherapy (group I) or those who did (group II). Clinicopathological characteristics, breast cancer-specific survival (BCSS), and overall survival (OS) were compared between the groups. In addition, a subgroup analysis for survival based on tumor size was conducted. Results A total of 252 N0 TN MBC patients with tumor sizes >1 cm who were diagnosed between April 1997 and March 2011 were enrolled. The median age was 44.95 years (range, 25–72 years), and the median follow-up period was 93.94 months (range, 23–195 months). Overall, the BCSS and OS in group II (97.3% and 97.3%, respectively) were significantly better compared with those in group I (89.2% and 86.2%, respectively). In the subgroup analysis, in patients with tumors >2 cm in size, those in group II had significant better BCSS and OS (97.5% and 97.5%, respectively) compared with those in group I (78.3% and 73.9%, respectively). In contrast in those with tumors 1–2 cm in size, there were no significant differences in BCSS and OS between the groups (both 97.1% for group I, and 95.2% and 92.9%, respectively for group II). Multivariate analysis revealed that adjuvant chemotherapy significantly improved BCSS (P = 0.009) and OS (P = 0.007), but only for patients with larger tumors (>2 cm). Conclusions In patients with N0 TN MBC, adjuvant chemotherapy had a significant clinical survival benefit, but only in those with tumors >2 cm.

【 授权许可】

CC BY